2025 United Kingdom Ai-Based Clinical Trials Revenue Opportunities Report
Description
The 2025 United Kingdom Ai-Based Clinical Trials Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest AI-based companies actively participating in clinical trials in the United Kingdom are BenevolentAI, Exscientia, IQVIA, and Phesi. BenevolentAI, headquartered in London, uses AI and machine learning to accelerate drug discovery and has formed key partnerships with pharmaceutical giants such as AstraZeneca, driving its drugs into clinical trials. Exscientia, also UK-based, specializes in AI-driven drug design, optimizing molecules for development with a focus on various diseases. IQVIA, a global CRO with UK operations, combines advanced analytics and clinical research services, supporting clinical trials through technology and data solutions. Phesi leverages patient-centric AI analytics for trial design and recruitment, boasting a platform with digital patient profiles across millions of cases to enhance trial efficiency.
These companies utilize AI platforms that integrate vast clinical and biological datasets to improve trial design, patient selection, and drug candidate identification. BenevolentAI’s and Exscientia’s AI platforms enable rapid hypothesis generation and molecule optimization, while IQVIA offers comprehensive clinical trial analytics and technology solutions globally, including in the UK. Phesi’s AI-powered Trial Accelerator Platform reduces recruitment timelines using extensive patient data. Together, they represent the cutting edge of AI-enhanced clinical trials in the UK, contributing both to drug discovery pipelines and trial operational efficiency, supported by strategic industry collaborations and significant investment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the AI-based Clinical Trials by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest AI-based companies actively participating in clinical trials in the United Kingdom are BenevolentAI, Exscientia, IQVIA, and Phesi. BenevolentAI, headquartered in London, uses AI and machine learning to accelerate drug discovery and has formed key partnerships with pharmaceutical giants such as AstraZeneca, driving its drugs into clinical trials. Exscientia, also UK-based, specializes in AI-driven drug design, optimizing molecules for development with a focus on various diseases. IQVIA, a global CRO with UK operations, combines advanced analytics and clinical research services, supporting clinical trials through technology and data solutions. Phesi leverages patient-centric AI analytics for trial design and recruitment, boasting a platform with digital patient profiles across millions of cases to enhance trial efficiency.
These companies utilize AI platforms that integrate vast clinical and biological datasets to improve trial design, patient selection, and drug candidate identification. BenevolentAI’s and Exscientia’s AI platforms enable rapid hypothesis generation and molecule optimization, while IQVIA offers comprehensive clinical trial analytics and technology solutions globally, including in the UK. Phesi’s AI-powered Trial Accelerator Platform reduces recruitment timelines using extensive patient data. Together, they represent the cutting edge of AI-enhanced clinical trials in the UK, contributing both to drug discovery pipelines and trial operational efficiency, supported by strategic industry collaborations and significant investment.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
